文献速递结核与非结核分枝杆菌艾滋病与性传播感染

南非夸祖鲁-纳塔尔省接受新型及再利用药物治疗的耐多药/利福平耐药结核病女性的母体、妊娠及婴儿结局

Maternal, Pregnancy, and Infant Outcomes in Women Treated for Multidrug-Resistant/Rifampicin-Resistant Tuberculosis With Novel and Repurposed Drugs in KwaZulu-Natal, South Africa.
PubMed 文献 · Clin Infect Dis · 2026-01-01

这项前瞻性观察研究纳入2018年1月至2024年3月启动耐多药/利福平耐药结核病治疗的70名孕妇,其中53人(76%)合并HIV感染。44人(62.9%)获得有利结核治疗结局,23人(34.3%)出现不良妊娠结局,43名12月龄评估婴儿中27人(62.8%)结局良好,10人(23.3%)在出生第一年发展为结核病。

要点

  • 耐多药/利福平耐药结核病孕妇中HIV合并感染率高(76%),可能 contribute 不良妊娠结局。
  • 所有婴儿均暴露于贝达喹啉,需加强母婴支持性咨询和婴儿结核预防治疗。

核心结论

  • 高TB-HIV合并感染率可能 contribute 于不良妊娠结局。
  • 需要支持性母体依从性咨询和婴儿结核预防治疗以预防结核传播给婴儿。

研究设计与样本

  • 前瞻性观察研究,纳入2018年1月1日至2024年3月31日启动耐多药/利福平耐药结核病治疗的孕妇。
  • 共纳入70名孕妇,其中53名(76%)诊断为HIV感染。
  • 通过持续记录审查和临床评估记录母体结核治疗和妊娠结局,并描述婴儿结局。
  • 使用稳健标准误的泊松回归评估与有利母体治疗和妊娠结局相关的因素。

主要发现

  • 44名(62.9%)女性获得有利结核治疗结局。
  • 所有婴儿均暴露于贝达喹啉。
  • 23名(34.3%)女性出现不良妊娠结局,其中20名(29.8%)婴儿早产和/或低出生体重。

临床怎么用

  • 对耐多药/利福平耐药结核病孕妇应提供支持性母体依从性咨询。
  • 对暴露婴儿应提供结核预防治疗以预防结核传播。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is limited information on the safety and efficacy of new and repurposed second-line anti-tuberculosis (TB) drugs in pregnant women. METHODS: Pregnant women initiating treatment for multidrug-resistant/rifampicin-resistant (MDR/RR) TB from 1 January 2018 to 31 March 2024 were included in this prospective, observational study. Maternal TB treatment and pregnancy outcomes were documented through ongoing record reviews and clinical assessments conducted to describe infant outcomes. Using Poisson regression with robust standard errors, we evaluated factors associated with favorable maternal treatment and pregnancy outcomes. RESULTS: Of 70 pregnant women treated for MDR/RR TB, 53 (76%) were diagnosed with human immunodeficiency virus (HIV). Favorable TB treatment outcomes were reported in 44 (62.9%) women. Sixty-seven (95.7%) of the 70 infants were born alive;median gestational age 38 weeks (interquartile range [IQR], 37.0-39.0) and median birth weight 2970 g (IQR, 2560-3280). All infants were exposed to bedaquiline. Twenty-three (34.3%) women had unfavorable pregnancy outcomes, with 20 (29.8%) infants born prematurely and/or with low birth weight. Women with positive sputum smears at treatment initiation were less likely to have a favorable treatment outcome (adjusted risk ratio, 0.33; 95% confidence interval, .17-.66; P = .002). Of the 43 infants evaluated at 12 months, 27 (62.8%) had favorable outcomes, with 10 (23.3%) infants developing TB in their first year of life. CONCLUSIONS: The high TB-HIV coinfection rate is likely to have contributed to unfavorable pregnancy outcomes. Supportive maternal adherence counseling and infant TB preventive treatment are needed to prevent TB transmission to infants.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Loveday M, Hughes J, Mchunu N, et al. Maternal, Pregnancy, and Infant Outcomes in Women Treated for Multidrug-Resistant/Rifampicin-Resistant Tuberculosis With Novel and Repurposed Drugs in KwaZulu-Natal, South Africa. Clin Infect Dis. 2026. PMID: 41160716. doi:10.1093/cid/ciaf593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。